AN2 Therapeutics
phase part a phase pivotal clinical in treatment refractory mac lung disease not i laced confirmed anticipated trial design during meeting with activities underway phase part seamless enrollment | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
20 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
a phase pivotal clinical trial of in treatment refractory mac lung disease plan to use pathway in microbiological primary in japan to support potential registration phase part phase part an therapeutics | AN2 Therapeutics
Related slides by other companies
BioAtla
Investor Presentation
August 2023
encouraging phase results with | BioAtla
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
ATAI
Investor Presentation
April 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show consistent clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated good tolerability | ATAI
ATAI
Investor Presentation
March 2023
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by learning memory deficits no approved treatment in in predictive dose modeling phase concentration phase cognitive challenge phase a phase a a risked investigated excellent tolerability humans | ATAI
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io